{"id":476148,"date":"2020-03-25T13:38:01","date_gmt":"2020-03-25T13:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476148"},"modified":"2020-03-25T13:38:01","modified_gmt":"2020-03-25T13:38:01","slug":"chemotherapy-induced-anemia-market-size-share-market-trends-and-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapy-induced-anemia-market-size-share-market-trends-and-forecast-till-2030_476148.html","title":{"rendered":"Chemotherapy Induced Anemia Market Size & Share, Market trends and forecast till 2030"},"content":{"rendered":"
\"Chemotherapy<\/a><\/div>\n
DelveInsight’s “Chemotherapy Induced Anemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight<\/strong> launched its new report on Chemotherapy Induced Anemia – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/p>\n

DelveInsight’s “Chemotherapy Induced Anemia – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>” report delivers an in-depth understanding of the Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Key facts of the report:<\/strong>
1. The most common comorbid conditions before starting chemotherapy were hypertension (46.4%), diabetes (22.6%), and renal disease (11.2%).
2. The most common regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)\/rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (58.7%), followed by bendamustine with or without rituximab (11%).<\/p>\n

Key benefits of the report:<\/strong>
1. In the coming years, Chemotherapy Induced Anemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
2. The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Anemia R&D. The therapies under development are focused on novel approaches to treat\/improve the disease condition     
3. Major players are involved in developing therapies for Chemotherapy Induced Anemia. Launch of emerging therapies will significantly impact the Chemotherapy Induced Anemia market
4. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chemotherapy Induced Anemia<\/p>\n

\"\"<\/strong><\/p>\n

“Anemia is the most common and persistent hematological abnormality in oncology patients. Chemotherapy-induced anemia (CIA) is a consequence of malignant invasion of normal tissue leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation.”<\/strong><\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-anemia-market<\/strong><\/p>\n

Key pharma player involved in Chemotherapy Induced Anemia market:
<\/strong>1. FibroGen<\/p>\n

Emerging therapy for Chemotherapy Induced Anemia are:<\/strong>
1. Roxadustat<\/p>\n

Table of Contents:<\/strong>
1. Key Insights
2. Executive Summary of Chemotherapy Induced Anemia
3. Competitive Intelligence Analysis for Chemotherapy Induced Anemia
4. Chemotherapy Induced Anemia: Market Overview at a Glance
5. Chemotherapy Induced Anemia: Disease Background and Overview
6. Patient Journey
7. Chemotherapy Induced Anemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Chemotherapy Induced Anemia Treatment
11. Marketed Products
12. Emerging Therapies
13. Chemotherapy Induced Anemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Chemotherapy Induced Anemia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight<\/p>\n

Click here and download a free report on Chemotherapy Induced Anemia<\/a>.<\/strong><\/p>\n

Related reports:<\/strong> <\/p>\n

Chemotherapy-induced thrombocytopenia (CIT) – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/p>\n

Chemotherapy Induced Neutropenia (CIN) – Epidemiology Forecast to 2030<\/a><\/p>\n

Chemotherapy Induced Febrile Neutropenia – Epidemiology Forecast to 2030<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Yash Bhardwaj
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s “Chemotherapy Induced Anemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5 (Germany, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-476148","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476148"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476148\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}